← Search & browse all drugs
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › OTHER ANTINEOPLASTIC AGENTS › Poly (ADP-ribose) polymerase (PARP) inhibitors
niraparib
L01XK02
Adult Dosing
- Epithelial ovarian, fallopian tube, or primary peritoneal cancer (maintenance): 300 mg orally once daily
- Patients with baseline weight <77 kg or platelet count <150,000/mcL: 200 mg orally once daily
- Continue treatment until disease progression or unacceptable toxicity
Pediatric Dosing
- Safety and efficacy not established in pediatric patients
Indications
- Maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy
- Maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy
Mechanism of Action
- Inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1 and PARP2
- Plays a role in DNA repair, leading to synthetic lethality and cell death in cancer cells with deficient DNA homologous recombination repair (e.g., BRCA mutations)
Contraindications
- Hypersensitivity to niraparib or any of its excipients
Adverse Reactions
- Thrombocytopenia
- Anemia
- Neutropenia
- Leukopenia
- Palmar-plantar erythrodysesthesia syndrome
- Nausea and vomiting
- Fatigue
- Hypertension
- Headache
- Insomnia
- Myelodysplastic Syndrome / Acute Myeloid Leukemia (MDS/AML)
Drug Interactions
- Vaccines (live): Avoid administration; immunosuppressive effects of niraparib may enhance adverse effects or reduce vaccine efficacy
- Myelosuppressive agents: May potentiate hematologic toxicity; monitor blood counts closely
Curated Content: Needs Vetting Before Put to Clinical Use